Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


Last $34.60 USD
Change Today +0.97 / 2.88%
Volume 441.3K
EBS On Other Exchanges
Symbol
Exchange
Berlin
New York
As of 8:04 PM 02/10/16 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

400 Professional Drive

Gaithersburg, MD 20879

United States

Phone: 240-631-3200

Fax:

Emergent BioSolutions Inc., a specialty pharmaceutical company, develops and offers specialized products to healthcare providers and governments for use in addressing medical needs and emerging health threats. Divisions The company has two operating divisions, Biodefense and Biosciences. Biodefense This division is a specialty pharmaceutical business focused on countermeasures that address CBRNE (Chemical, Biological, Radiological, Nuclear and Explosives) threats. The United States government is the primary purchaser of the company’s Biodefense products and often provides it with substantial funding for the development of its Biodefense product candidates. The company’s Biodefense portfolio consists of five revenue generating products and various investigational stage product candidates. The company’s Biodefense division marketed products are BioThrax (Anthrax Vaccine Adsorbed), the vaccine licensed by the U.S. Food and Drug Administration (the FDA), for the prevention of anthrax disease; BAT (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-Equine), the only heptavalent therapeutic licensed by the FDA for the treatment of botulinum disease; Anthrasil (Anthrax Immune Globulin Intravenous (Human)), which has a pending Biologics License Application, with the FDA and, if approved, would be the only polyclonal antibody therapeutic licensed by the FDA for the treatment of anthrax infection; VIGIV (Vaccinia Immune Globulin Intravenous (Human)), the only therapeutic licensed by the FDA to address adverse events from smallpox vaccination; and RSDL (Reactive Skin Decontamination Lotion Kit), the only device cleared by the FDA for the removal or neutralization of chemical agents, T-2 toxin and many pesticide-related chemicals from the skin. The company is continuing to identify and pursue opportunities to expand the market for BioThrax to foreign governments, non-governmental organizations and multinational companies (including transportation, critical infrastructure services and security companies), as well as health care providers (including hospitals and clinics). The company’s Biodefense division investigational stage product candidates are NuThrax (anthrax vaccine adsorbed with CPG 7909 adjuvant), a next generation anthrax vaccine; PreviThrax (recombinant protective antigen anthrax vaccine, purified), a next generation anthrax vaccine; GC-072, the primary compound in the EV-035 series of spectrum antibiotics, which it acquired from Evolva SA in December 2014; and other Biodefense product candidates. The company’s Biodefense division also has programs targeted at providing solutions to the Ebola outbreak in West Africa, including an MVA-Ebola vaccine candidate, anti-Ebola monoclonal antibody product candidates and an Ebola hyperimmune product candidate. The company has responded to Task Order Requests issued by the Biomedical Advanced Research and Development Authority (BARDA), for the manufacture of Ebola medical countermeasures as part of its Center for Innovation in Advanced Development and Manufacturing (CIADM), program. In addition, it has a license agreement for the manufacture of VAX161C, a clinical stage recombinant pandemic influenza vaccine product candidate being developed by VaxInnate, Inc., in the event of a surge order from BARDA. NuThrax is positioned for a Phase 3 clinical trial. Marketing and Sales The company markets and sells its Biodefense products to the U.S. government and domestic non-government organizations with a small, specialized marketing and sales group. Research and Development Gross research and development expenses for the Biodefense division for the year ended December 31, 2014, totaled approximately $82.0 million. Biosciences This division is a specialty pharmaceutical business focused on therapeutics and vaccines in hematology/oncology, transplantation, infectious disease and autoimmunity. The company’s Biosciences portfolio consists of four revenue generating products, all of which were acquired through its acquisition of Cangene Corporation in February 2014, as well as various investigational stage product candidates and a contract manufacturing servi

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EBS:US $34.60 USD +0.97

EBS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Albany Molecular Research Inc $15.49 USD +0.44
Bavarian Nordic A/S kr246.50 DKK +18.50
Depomed Inc $15.47 USD -0.34
Impax Laboratories Inc $32.18 USD -0.26
Nektar Therapeutics $11.17 USD -0.17
View Industry Companies
 

Industry Analysis

EBS

Industry Average

Valuation EBS Industry Range
Price/Earnings 29.7x
Price/Sales 2.6x
Price/Book 2.2x
Price/Cash Flow 22.0x
TEV/Sales 1.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact EMERGENT BIOSOLUTIONS INC, please visit www.emergentbiosolutions.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.